看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯，血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。: e2 [" [* z0 I7 q# z$ v- L# d. ?
) l, O* T9 }4 Z4 S9 o2 a5 f M
8 A6 P, I6 _% L( aCurrently available feasibility data for possible combination strategies.
" V$ I' E- L* s————————————————————————————————
, Y3 D5 b! y: z( j1 A5 k+ TCombination Feasibility according to preliminary data ; Z" I$ g& ^5 t% r# R! O" y
——————————————————————————————————. ?% K2 l5 g; z
Bevacizumab + sorafenib Yes, reduced dose
. d5 d7 D" ^1 qBevacizumab + sunitinib† No
4 y$ z7 J8 T N% F, T# F9 qBevacizumab + temsirolimus Yes
/ j5 }5 y4 q% L+ V- t& C+ yBevacizumab + everolimus Yes
8 d" \; i# m [6 ~! T5 a8 @Sorafenib + sunitinib ? * z- d& F2 v* l9 P6 ]: ~% X
Sorafenib + temsirolimus Yes, reduced dose # S* b5 W" c! w$ R% a; x
Sorafenib + everolimus Yes, reduced dose
9 O: ~; I: p7 i& o; G" J& pSunitinib + temsirolimus† No " [2 }2 L. B; [9 G
Sunitinib + everolimus ?
l3 U7 `8 I6 G8 n" yTemsirolimus + everolimus ?
9 v; K* h# g$ h+ ~1 I) X4 X————————————————————
# K( N0 g! D) M6 ?†Led to US FDA warning.! \6 S. U6 j) j* \! P
?: As yet unattempted combination.& w8 }6 c( z, O) e d
|
显身卡
; z% p( G7 w |" A1 m; n
